Home > Investors > ASX Announcements

ASX Announcements

9-May-2024	Trading Update

3-May-2024	Secondary Trading Notice

3-May-2024	Application for quotation of securities - ME1

2-May-2024	Proposed issue of securities - ME1

2-May-2024	Consolidation/Split - ME1

2-May-2024	Notice of Annual General Meeting/Proxy Form

30-Apr-2024	Final Director's Interest Notice

30-Apr-2024	Proposed issue of securities - ME1

30-Apr-2024	Appointment of Tim Tian as Group CFO

30-Apr-2024	Quarterly Activities/Appendix 4C Cash Flow Report

30-Apr-2024	Board Change

22-Apr-2024	Update - Proposed issue of securities - ME1

22-Apr-2024	Secondary Trading Notice

22-Apr-2024	Application for quotation of securities - ME1

19-Apr-2024	Proposed issue of securities - ME1

19-Apr-2024	Corporate Update

19-Apr-2024	Response to ASX Aware Letter

16-Apr-2024	ME1 Q1 FY24 Revenue

9-Apr-2024	Proposed issue of securities - ME1

9-Apr-2024	Application for quotation of securities - ME1

9-Apr-2024	Health House Australia and Corporate Update

8-Apr-2024	Extension of Cleansing Offer Closing Date

2-Apr-2024	Proposed issue of securities - ME1

2-Apr-2024	Application for quotation of securities - ME1

2-Apr-2024	Mernova Trading Update

28-Mar-2024	Annual Report to shareholders

28-Mar-2024	Appendix 4G and Corporate Governance Statement

27-Mar-2024	ME1 Q1 FY24 Revenue Update

26-Mar-2024	Application for quotation of securities - ME1

26-Mar-2024	Application for quotation of securities - ME1

26-Mar-2024	Application for quotation of securities - ME1

25-Mar-2024	Notification regarding unquoted securities - ME1

25-Mar-2024	Application for quotation of securities - ME1

25-Mar-2024	Disclosure Document

11-Mar-2024	Response to ASX Query

29-Feb-2024	FY 2023 Results

29-Feb-2024	Preliminary Final Report

28-Feb-2024	Secondary Trading Notice

28-Feb-2024	Application for quotation of securities - ME1

27-Feb-2024	Secondary Trading Notice

27-Feb-2024	Application for quotation of securities - ME1

21-Feb-2024	Proposed issue of securities - ME1

21-Feb-2024	Proposed issue of securities - ME1

21-Feb-2024	Capital Raising & Corporate Update

21-Feb-2024	Proposed issue of securities - ME1

21-Feb-2024	Proposed issue of securities - ME1

19-Feb-2024	Trading Halt

12-Feb-2024	Mernova Continues Strong Performance in Q1 FY24

7-Feb-2024	HHI Revenue Update

5-Feb-2024	Mernova Revenue Update

2-Feb-2024	Appendix 2A x2 and Secondary Trading Notice

2-Feb-2024	Completion of Share Consolidation

31-Jan-2024	Quarterly Activities/Appendix 4C Cash Flow Report

23-Jan-2024	Results of Meeting

19-Jan-2024	Change of Director's Interest Notice x 2

19-Jan-2024	Notification of cessation of securities - ME1

16-Jan-2024	Mernova Revenue Update and Placement

16-Jan-2024	Application for quotation of securities - ME1

16-Jan-2024	Proposed issue of securities - ME1

27-Dec-2023	Notification of cessation of securities - ME1

22-Dec-2023	Consolidation/Split - ME1

22-Dec-2023	Notice of General Meeting/Proxy Form

22-Dec-2023	Proposed issue of securities - ME1

22-Dec-2023	Proposed issue of securities - ME1

22-Dec-2023	Proposed issue of securities - ME1

22-Dec-2023	Proposed issue of securities - ME1

22-Dec-2023	Company Secretary Appointment/Resignation

14-Dec-2023	Response to Aware Query

13-Dec-2023	Group Revenue Update

8-Dec-2023	Change of Director's Interest Notice

8-Dec-2023	Change in substantial holding

7-Dec-2023	Cleansing Notice

7-Dec-2023	Application for quotation of securities - ME1

7-Dec-2023	Corporate Update

7-Dec-2023	Proposed issue of securities - ME1

7-Dec-2023	Proposed issue of securities - ME1

29-Nov-2023	Application for quotation of securities - ME1

27-Nov-2023	Application for quotation of securities - ME1

22-Nov-2023	Extension of Prospectus Offer Closing Date

22-Nov-2023	Change of Auditor

21-Nov-2023	Application for quotation of securities - ME1

20-Nov-2023	Change of Director's Interest Notice x 4

20-Nov-2023	Application for quotation of securities - ME1

17-Nov-2023	Application for quotation of securities - ME1

17-Nov-2023	Application for quotation of securities - ME1

17-Nov-2023	Application for quotation of securities - ME1

17-Nov-2023	Application for quotation of securities - ME1

16-Nov-2023	Application for quotation of securities - ME1

16-Nov-2023	Notification regarding unquoted securities - ME1

16-Nov-2023	Application for quotation of securities - ME1

16-Nov-2023	Application for quotation of securities - ME1

15-Nov-2023	Change of Director's Interest Notice

15-Nov-2023	Health House Australia Revenue Update

13-Nov-2023	Top 20 Holders

13-Nov-2023	Distribution Schedule

13-Nov-2023	Application for quotation of securities - ME1

13-Nov-2023	Cancel - Proposed issue of securities - ME1

13-Nov-2023	Cancel - Proposed issue of securities - ME1

13-Nov-2023	Proposed issue of securities - ME1

13-Nov-2023	Proposed issue of securities - ME1

13-Nov-2023	Capital Raising Re-Price & Prospectus Offers Extension

10-Nov-2023	Application for quotation of securities - ME1

10-Nov-2023	Notification regarding unquoted securities - ME1

10-Nov-2023	Notification regarding unquoted securities - ME1

9-Nov-2023	Trading Halt

8-Nov-2023	Update - Proposed issue of securities - ME1

6-Nov-2023	Proposed issue of securities - ME1

6-Nov-2023	Supplementary Prospectus - Bonus Options

3-Nov-2023	Change of Director's Interest Notice x 4

3-Nov-2023	Change in substantial holding

3-Nov-2023	Ceasing to be a substantial holder

2-Nov-2023	Application for quotation of securities - ME1

2-Nov-2023	Becoming a substantial holder

2-Nov-2023	Mernova Revenue Update

31-Oct-2023	Quarterly Activities/Appendix 4C Cash Flow Report

31-Oct-2023	Update - Proposed issue of securities - ME1

31-Oct-2023	Prospectus - Bonus Options

30-Oct-2023	Application for quotation of securities - ME1

27-Oct-2023	Proposed issue of securities - ME1

27-Oct-2023	Proposed issue of securities - ME1

27-Oct-2023	Cleansing Notice

27-Oct-2023	Notification regarding unquoted securities - ME1

27-Oct-2023	Application for quotation of securities - ME1

27-Oct-2023	Application for quotation of securities - ME1

27-Oct-2023	Application for quotation of securities - ME1

27-Oct-2023	Application for quotation of securities - ME1

27-Oct-2023	Application for quotation of securities - ME1

27-Oct-2023	Application for quotation of securities - ME1

26-Oct-2023	Change of Director's Interest Notice

26-Oct-2023	Notification of cessation of securities - ME1

26-Oct-2023	Cleansing Notice

26-Oct-2023	Application for quotation of securities - ME1

26-Oct-2023	Application for quotation of securities - ME1

26-Oct-2023	Proposed issue of securities - ME1

26-Oct-2023	Capital Raising & Corporate Update

26-Oct-2023	Proposed issue of securities - ME1

26-Oct-2023	Proposed issue of securities - ME1

26-Oct-2023	Proposed issue of securities - ME1

24-Oct-2023	Application for quotation of securities - ME1

24-Oct-2023	Proposed issue of securities - ME1

24-Oct-2023	Application for quotation of securities - ME1

24-Oct-2023	Trading Halt

23-Oct-2023	Proposed issue of securities - ME1

23-Oct-2023	Bonus Issue of Options and Other Corporate Updates

20-Oct-2023	Mernova Q4 Revenue and New Purchase Orders Update

18-Oct-2023	Application for quotation of securities - ME1

18-Oct-2023	Application for quotation of securities - ME1

18-Oct-2023	Application for quotation of securities - ME1

18-Oct-2023	Application for quotation of securities - ME1

18-Oct-2023	Results of General Meeting

18-Oct-2023	Melodiol Group Q3 Revenue Update

16-Oct-2023	HHI Australian Operations Results Update

12-Oct-2023	Halucenex Phase II Clinical Trial Update

9-Oct-2023	Mernova Q3 Revenue Update

25-Sep-2023	Mernova New Purchase Orders Update

12-Sep-2023	Proposed issue of securities - ME1

12-Sep-2023	Notice of General Meeting/Proxy Form

11-Sep-2023	Mernova Maiden Alberta PO and Revenue Update

5-Sep-2023	Proposed issue of securities - ME1

4-Sep-2023	Cleansing Notice

4-Sep-2023	Debt Restructure Update

4-Sep-2023	Application for quotation of securities - ME1

4-Sep-2023	ImpACTIVE Sponsorship Deal & Promising Regulatory Shifts

31-Aug-2023	Half Year Results Commentary

31-Aug-2023	Half Yearly Report and Accounts

28-Aug-2023	Application for quotation of securities - ME1

21-Aug-2023	Mernova Q3 Sales Update

18-Aug-2023	Restricted Securities to be Released from Escrow

14-Aug-2023	Cleansing Notice

14-Aug-2023	Application for quotation of securities - ME1

11-Aug-2023	Response to ASX Aware Query

9-Aug-2023	Cleansing Notice

8-Aug-2023	Application for quotation of securities - ME1

8-Aug-2023	Application for quotation of securities - ME1

8-Aug-2023	Proposed issue of securities - ME1

8-Aug-2023	Proposed issue of securities - ME1

8-Aug-2023	Proposed issue of securities - ME1

8-Aug-2023	Capital Raising and Debt to Equity Conversions

4-Aug-2023	Trading Halt

2-Aug-2023	LOI for Sale of Sierra Sage and Halucenex to Panacea

31-Jul-2023	Cancel - Proposed issue of securities - ME1

31-Jul-2023	Quarterly Activities/Appendix 4C Cash Flow Report

26-Jul-2023	Mernova Makes Strong Progress on EU GMP Licence Process

24-Jul-2023	Subsidiary HHI Delivers Strong Revenue & EBITDA in H1 2023

21-Jul-2023	Notification of cessation of securities - ME1

19-Jul-2023	Strong Start to Q3 CY2023 with $1.6m in New Revenue & POs

13-Jul-2023	Record Revenue Quarter With Group Sales Up 105%

10-Jul-2023	Mernova Delivers Record Half Yearly Revenues

7-Jul-2023	Notification regarding unquoted securities - ME1

7-Jul-2023	Application for quotation of securities - ME1

6-Jul-2023	Change of Director's Interest Notice x2

3-Jul-2023	Health House International Revenue Update

30-Jun-2023	Appendix 3G

30-Jun-2023	Appendix 2A

26-Jun-2023	Appendix 2A

26-Jun-2023	Appendix 3H

21-Jun-2023	Appendix 2A

21-Jun-2023	Change in substantial holding

19-Jun-2023	Appendix 3B - Amendment

19-Jun-2023	Appendix 3B

15-Jun-2023	Appendix 3G

15-Jun-2023	Appendix 2A

15-Jun-2023	Disclosure Document

14-Jun-2023	Appendix 3B

14-Jun-2023	Appendix 2A

14-Jun-2023	Debt Conversions and Extensions

13-Jun-2023	Change of Company Name and ASX Code

9-Jun-2023	Notification regarding unquoted securities - CPH

9-Jun-2023	LOI to Import MDMA & Psilocybin Treatments to Australia

9-Jun-2023	LOI to Import MDMA & Psilocybin Treatments to Australia

8-Jun-2023	Application for quotation of securities - CPH

6-Jun-2023	Notification of cessation of securities - CPH

5-Jun-2023	Mernova Appoints CannDelta to Map EU GMP Export Process

2-Jun-2023	Notification regarding unquoted securities - CPH

2-Jun-2023	Cleansing Notice - Convertible Notes

31-May-2023	Results of Meeting

24-May-2023	SBC Facility - Second Purchase & Amortisation Payments

24-May-2023	Application for quotation of securities - CPH

24-May-2023	Proposed issue of securities - CPH

24-May-2023	Application for quotation of securities - CPH

24-May-2023	Cleansing Notice

24-May-2023	Application for quotation of securities - CPH

24-May-2023	Notification of cessation of securities - CPH

24-May-2023	Application for quotation of securities - CPH

24-May-2023	Application for quotation of securities - CPH

22-May-2023	Mernova Q2 Sales Update

19-May-2023	Proposed issue of securities - CPH

19-May-2023	Proposed issue of securities - CPH

19-May-2023	Proposed issue of securities - CPH

19-May-2023	Capital Raising & Debt Repayment

17-May-2023	Trading Halt

16-May-2023	Notification regarding unquoted securities - CPH

16-May-2023	Response to Financial Condition Query

16-May-2023	Application for quotation of securities - CPH

15-May-2023	Results of Meeting

15-May-2023	Creso Pharma Expands Asia Market Footprint

10-May-2023	Response to ASX Price Query

10-May-2023	Sierra Sage Herbs LLC Update

5-May-2023	Halucenex Phase II Clinical Trial Update

2-May-2023	Application for quotation of securities - CPH

1-May-2023	Notice of Annual General Meeting/Proxy Form

1-May-2023	Mernova - Eighth Province Entry & $553k in New POs

28-Apr-2023	Quarterly Activities/Appendix 4C Cash Flow Report

19-Apr-2023	Mernova - Q1 Cashflow Positive With Record Revenues

14-Apr-2023	ASX Listing Rule 3.13.1 Notice Regarding AGM

14-Apr-2023	Notice of General Meeting/Proxy Form

6-Apr-2023	February Placement Update & Additional Information

31-Mar-2023	Appendix 4G and Corporate Governance Statement

31-Mar-2023	Annual Report to Shareholders

29-Mar-2023	Notification of cessation of securities - CPH

15-Mar-2023	Notification regarding unquoted securities - CPH

13-Mar-2023	Resolution of Historical ASX Listing Rule Breach

13-Mar-2023	Censure of Creso Pharma Limited

13-Mar-2023	Cleansing Notice - Convertible Notes

7-Mar-2023	Application for quotation of securities - CPH

6-Mar-2023	Cancel - Proposed issue of securities - CPH

6-Mar-2023	Proposed issue of securities - CPH

6-Mar-2023	Proposed issue of securities - CPH

6-Mar-2023	Proposed issue of securities - CPH

6-Mar-2023	Proposed issue of securities - CPH

6-Mar-2023	$2.5M Con Note Issue, Rollover & Extinguishment of Debt

28-Feb-2023	Creso Reports Strong Financial Performance in FY22

28-Feb-2023	Preliminary Final Report

24-Feb-2023	Secondary Trading Notice

24-Feb-2023	Application for quotation of securities - CPH

17-Feb-2023	Proposed issue of securities - CPH

17-Feb-2023	CPH Secures Firm Commitments to Raise $2m

15-Feb-2023	Notification of cessation of securities - CPH

15-Feb-2023	Trading Halt

14-Feb-2023	Restricted Securities to be Released from Escrow

9-Feb-2023	Creso reports strong progress across business units

7-Feb-2023	Halucenex to pursue AUS entry after landmark TGA decision

3-Feb-2023	Change of Director's Interest Notice x 2

2-Feb-2023	Distribution Schedule

2-Feb-2023	Top 20 securityholders

2-Feb-2023	Appendix 2A

31-Jan-2023	Application for quotation of securities - CPH

31-Jan-2023	Quarterly Activities/Appendix 4C Cash Flow Report

27-Jan-2023	Notification regarding unquoted securities - CPH

27-Jan-2023	Notification regarding unquoted securities - CPH

27-Jan-2023	Proposed issue of securities - CPH

27-Jan-2023	Disclosure Document

27-Jan-2023	Proposed issue of securities - CPH

27-Jan-2023	Proposed issue of securities - CPH

27-Jan-2023	La Plata Debt Restructure & Abby and Finn LOI

27-Jan-2023	Application for quotation of securities - CPH

27-Jan-2023	Proposed issue of securities - CPH

27-Jan-2023	Application for quotation of securities - CPH

25-Jan-2023	Trading Halt

25-Jan-2023	Pause in Trading

24-Jan-2023	Mernova - New Province Entry & Largest Ever PO

17-Jan-2023	Application for quotation of securities - CPH

17-Jan-2023	Change of Director's Interest Notice x3

12-Jan-2023	Notification regarding unquoted securities - CPH

12-Jan-2023	Notification regarding unquoted securities - CPH

12-Jan-2023	Notification of cessation of securities - CPH

11-Jan-2023	Mernova wins seven new product listings in Nova Scotia

10-Jan-2023	Secondary Trading Notice

10-Jan-2023	Application for quotation of securities - CPH

10-Jan-2023	Application for quotation of securities - CPH

10-Jan-2023	Application for quotation of securities - CPH

10-Jan-2023	Proposed issue of securities - CPH

10-Jan-2023	ZLD: Receipt of Creso Shares and Settlement of HHI loan

9-Jan-2023	Creso raises $500k in convertible notes

9-Jan-2023	Application for quotation of securities - CPH

9-Jan-2023	Notification regarding unquoted securities - CPH

29-Dec-2022	Results of Meeting

22-Dec-2022	Top 20 Holder Report

20-Dec-2022	Notice of Expiry of Listed Options

15-Dec-2022	Proposed issue of securities - CPH

15-Dec-2022	Secured Convertible Notes Offer Update

12-Dec-2022	Notification regarding unquoted securities - CPH

8-Dec-2022	Extension of March Options Offer under Prospectus

7-Dec-2022	Halucenex administers first dose

5-Dec-2022	Response to ASX Query

2-Dec-2022	Notification regarding unquoted securities - CPH

2-Dec-2022	Application for quotation of securities - CPH

2-Dec-2022	Application for quotation of securities - CPH

2-Dec-2022	Initial Director's Interest Notice

2-Dec-2022	Final Director's Interest Notice

1-Dec-2022	Board Changes

28-Nov-2022	Proposed issue of securities - CPH

28-Nov-2022	Prospectus

25-Nov-2022	Notice of General Meeting/Proxy Form

23-Nov-2022	HHI Update & Product Registration Achieved in South Korea

22-Nov-2022	Creso is no longer the subject of ASIC Investigation

22-Nov-2022	Pause in trading

21-Nov-2022	Proposed issue of securities - CPH

21-Nov-2022	Proposed issue of securities - CPH

21-Nov-2022	ZLD: Partial Receipt and variation of Health House loan

18-Nov-2022	Mernova Update

17-Nov-2022	Replacement of Chairman

9-Nov-2022	Sierra Sage Herbs LLC Expands into Canada

3-Nov-2022	Secondary Trading Notice

3-Nov-2022	Application for quotation of securities - CPH

3-Nov-2022	Mernova Secures Cannabis 2.0 Sales License

1-Nov-2022	Quarterly Activities/Appendix 4C Cash Flow Report

1-Nov-2022	Proposed issue of securities - CPH

1-Nov-2022	CPH Secures Commitments to Raise up to $7.6m

28-Oct-2022	Trading Halt

25-Oct-2022	Change of Director's Interest Notice

25-Oct-2022	Notice of Breach of ASX Listing Rule 10.11

19-Oct-2022	Application for quotation of securities - CPH

17-Oct-2022	Final Director's Interest Notice

14-Oct-2022	Initial Director's Interest Notice x2

13-Oct-2022	Sierra Sage enters into agreement with accelerate360

10-Oct-2022	Melodiol Global Health - Rebranding Strategy

10-Oct-2022	Board Transition & Change of Company Name

10-Oct-2022	Proposed issue of securities - CPH

6-Oct-2022	Halucenex completes clinical trial patient recruitment

4-Oct-2022	Mernova Update

29-Sep-2022	Mernova Update

20-Sep-2022	Notification of cessation of securities - CPH

14-Sep-2022	Halucenex Update

6-Sep-2022	Change of Director's Interest Notice

6-Sep-2022	Becoming a substantial holder

2-Sep-2022	Sierra Sage secures US$214,000 purchase order from Walmart

31-Aug-2022	Half Yearly Report and Accounts

31-Aug-2022	Secondary Trading Notice

29-Aug-2022	Notification regarding unquoted securities - CPH

29-Aug-2022	Application for quotation of securities - CPH

29-Aug-2022	Creso Pharma completes Sierra Sage Herbs LLC Acquisition

29-Aug-2022	Application for quotation of securities - CPH

22-Aug-2022	Halucenex Update

15-Aug-2022	Secondary Trading Notice

15-Aug-2022	Application for quotation of securities - CPH

15-Aug-2022	Proposed issue of securities - CPH

15-Aug-2022	impACTIVE appoints New Brand Ambassador, Kolby Tullier

9-Aug-2022	Results of Meeting

8-Aug-2022	Proposed issue of securities - CPH

8-Aug-2022	Application for quotation of securities - CPH

8-Aug-2022	Mernova Update

4-Aug-2022	Proposed issue of securities - CPH

4-Aug-2022	Reinstatement to Official Quotation

4-Aug-2022	Capital Raising & Q2 22 Quarterly Activities Report Updates

2-Aug-2022	Extension to Voluntary Suspension

1-Aug-2022	Quarterly Activities/Appendix 4C Cash Flow Report

29-Jul-2022	HHI: Creso makes non-binding ind.proposal to acquire HHI

29-Jul-2022	Execution of non-binding term sheet to acquire Health House

29-Jul-2022	Suspension from Quotation

28-Jul-2022	Change of Director's Interest Notice

28-Jul-2022	Notification of cessation of securities - CPH

27-Jul-2022	Trading Halt

25-Jul-2022	SSH secures Private Label Manufacturing Agreement

21-Jul-2022	Mernova Update

18-Jul-2022	Halucenex Update

14-Jul-2022	Proposed issue of securities - CPH

14-Jul-2022	Application for quotation of securities - CPH

14-Jul-2022	Creso Pharma ImpACTIVE appoints three new brand ambassadors

12-Jul-2022	LOI secured with Providence Animal Health Korea Ltd

11-Jul-2022	Notice of General Meeting/Proxy Form

7-Jul-2022	HoA secured to launch SSH products in Singapore

30-Jun-2022	Heads of Agreement secured to launch SSH products in Taiwan

28-Jun-2022	Mernova Update

15-Jun-2022	Application for quotation of securities - CPH

15-Jun-2022	Application for quotation of securities - CPH

15-Jun-2022	Notification of cessation of securities - CPH

14-Jun-2022	Mernova Update

31-May-2022	Amended Constitution

31-May-2022	Results of Meeting

30-May-2022	Halucenex Enters into Supply Agreement with Optimi Health

23-May-2022	Creso Secures Heads of Agreement with Dr Pickles

10-May-2022	Halucenex Secures Import Permit from Health Canada

3-May-2022	Investor Presentation

29-Apr-2022	Quarterly Activities/Appendix 4C Cash Flow Report

28-Apr-2022	Notice of Annual General Meeting/Proxy Form

12-Apr-2022	ASX Listing Rule 3.13.1 Notice Regarding AGM

7-Apr-2022	Sierra Sage Increases to 110,000 Points of Sale

5-Apr-2022	US ROADSHOW - COMPANY PRESENTATION

5-Apr-2022	Notification regarding unquoted securities - CPH

5-Apr-2022	Application for quotation of securities - CPH

4-Apr-2022	US House of Representatives Passes Cannabis Act

1-Apr-2022	Proposed issue of securities - CPH

1-Apr-2022	Notification of cessation of securities - CPH

1-Apr-2022	LOI Secured with Laboratorios Brouwer for LATAM Market

28-Mar-2022	Halucenex Update

21-Mar-2022	Mernova reaches significant market share milestone

16-Mar-2022	Sierra Sage to unlock US product sales and manufacturing

4-Mar-2022	Secondary Trading Notice

2-Mar-2022	Notification of cessation of securities - CPH

2-Mar-2022	Application for quotation of securities - CPH

28-Feb-2022	Appendix 4G and Corporate Governance Statement

28-Feb-2022	Appendix 4E and Annual Report to Shareholders

28-Feb-2022	Halucenex secures Clinical Trial Authorisation

25-Feb-2022	Reinstatement to Official Quotation

25-Feb-2022	Proposed issue of securities - CPH

25-Feb-2022	Creso Pharma secures commitments to raise $5m

24-Feb-2022	Suspension From Official Quotation

22-Feb-2022	Trading Halt

21-Feb-2022	Mernova Operational Update

15-Feb-2022	Update on Acquisition of Sierra Sage Herbs

11-Feb-2022	Creso Pharma to Develop New Hemp-Based Lozenge Product

8-Feb-2022	Halucenex Update

3-Feb-2022	Proposed issue of securities - CPH

3-Feb-2022	Investor Presentation - Sierra Sage Acquisition

3-Feb-2022	Creso to enter US CBD Market through Sierra Sage Acquisition

31-Jan-2022	Quarterly Activities/Appendix 4C Cash Flow Report

28-Jan-2022	Application for quotation of securities - CPH

28-Jan-2022	Application for quotation of securities - CPH

25-Jan-2022	Halucenex Lodges Clinical Trial Authorisation

24-Jan-2022	Initial Director's Interest Notice x3

24-Jan-2022	Executive Director Remuneration

17-Jan-2022	Proposed issue of securities - CPH

17-Jan-2022	Creso Pharma Announces Three New Board Appointments

11-Jan-2022	Halucenex Update

6-Jan-2022	Release of Shares from Voluntary Escrow

21-Dec-2021	Application for quotation of securities - CPH

9-Dec-2021	Conversion of Performance Shares

9-Dec-2021	Application for quotation of securities - CPH

8-Dec-2021	Application for quotation of securities - CPH

7-Dec-2021	Mernova on track for quarter-on-quarter revenue growth

2-Dec-2021	Halucenex Awarded Dealer's License Amendment

30-Nov-2021	Trading Halt

25-Nov-2021	Update on Price and Volume Query Response

23-Nov-2021	Trading Halt

23-Nov-2021	Pause in Trading

17-Nov-2021	Application for quotation of securities - CPH

17-Nov-2021	Notification of cessation of securities - CPH

16-Nov-2021	Response to ASX Price and Volume Query

16-Nov-2021	Trading Halt

16-Nov-2021	Pause in Trading

15-Nov-2021	Creso Pharma Completes Integration of ImpACTIVE Assets

11-Nov-2021	Creso Pharma Anticipates Increasing Q4 2021 Swiss Revenue

9-Nov-2021	Dr Brian Walker Resigns as Strategic Consultant

8-Nov-2021	Change of Director's Interest Notice x 3

8-Nov-2021	Halucenex Receives Positive USP 61 and USP 62 Results

5-Nov-2021	Notification regarding unquoted securities - CPH

4-Nov-2021	Proposed issue of securities - CPH

4-Nov-2021	Appointment of Hon. Dr Brian Walker as Strategic Advisor

2-Nov-2021	Top 20 Holders

2-Nov-2021	Distribution Schedule

2-Nov-2021	Application for quotation of securities - CPH

1-Nov-2021	Creso Pharma to Enter Swiss Medicinal Cannabis Market

29-Oct-2021	Quarterly Activities/Appendix 4C Cash Flow Report

27-Oct-2021	Application for quotation of securities - CPH

26-Oct-2021	Secondary Trading Notice

26-Oct-2021	Proposed issue of securities - CPH

26-Oct-2021	Prospectus - Bonus Options

25-Oct-2021	Creso Completes Acquisition of the Assets of ImpACTIVE

25-Oct-2021	Notification regarding unquoted securities - CPH

25-Oct-2021	Application for quotation of securities - CPH

25-Oct-2021	Proposed issue of securities - CPH

25-Oct-2021	Proposed issue of securities - CPH

25-Oct-2021	Creso Pharma to Acquire ImpACTIVE Holdings Ltd Assets

11-Oct-2021	Mernova Completes THC Content Testing on New Strains

6-Oct-2021	Halucenex Update

5-Oct-2021	Mernova Secures over A$800,000 in New Purchase Orders

5-Oct-2021	Pause in Trading

20-Sep-2021	Halucenex Secures Research Agreement with Acadia University

20-Sep-2021	Pause in Trading

17-Sep-2021	Creso Pharma Launches New E-commerce Channels

13-Sep-2021	Secondary Trading Notice

13-Sep-2021	Creso Secures New Purchase Orders for Human Health Products

9-Sep-2021	Investor Presentation

6-Sep-2021	Notification regarding unquoted securities - CPH

6-Sep-2021	Proposed issue of securities - CPH

6-Sep-2021	Application for quotation of securities - CPH

6-Sep-2021	Creso Pharma Strengthens Management & Executive Team

31-Aug-2021	Half Yearly Report and Accounts

31-Aug-2021	Notification regarding unquoted securities - CPH

31-Aug-2021	NASDAQ Listing & RLH Merger Update

23-Aug-2021	Notification of cessation of securities - CPH

23-Aug-2021	Halucenex Commissions Extraction Unit

16-Aug-2021	Halucenex Awarded Dealer's License from Health Canada

12-Aug-2021	Trading Halt

12-Aug-2021	Pause in Trading

11-Aug-2021	Mernova secures medicinal cannabis sales licence & new POs

4-Aug-2021	Halucenex Continues to Make Progress ahead of Clinical Trial

2-Aug-2021	Quarterly Update & Appendix 4C

30-Jul-2021	Exercise of Options

30-Jul-2021	Application for quotation of securities - CPH

30-Jul-2021	Notification of cessation of securities - CPH

30-Jul-2021	Mernova to Introduce Fourteen New Strains

23-Jul-2021	Halucenex enters into a MOU with Landing Strong

20-Jul-2021	Bruce Linton Confirms Position

16-Jul-2021	CPH Launches cannaDOL through Multiple Distribution Channels

15-Jul-2021	Change of Director's Interest Notice x 3

15-Jul-2021	Creso Pharma Completes the Acquisition of Halucenex

15-Jul-2021	Appendix 2A

15-Jul-2021	Appendix 3G

15-Jul-2021	Secondary Trading Notice

13-Jul-2021	Notification of cessation of securities - CPH

9-Jul-2021	Application for quotation of securities - CPH

9-Jul-2021	Creso Completes Import Procedure in Uruguay for anibidiol

7-Jul-2021	Change in substantial holding

7-Jul-2021	Change of Director's Interest Notice

6-Jul-2021	Creso Secures First Purchase Order from Red Light Holland

2-Jul-2021	Halucenex Update

1-Jul-2021	Reinstatement to Official Quotation

1-Jul-2021	Creso's Second Consecutive Quarter of Record Revenue Growth

29-Jun-2021	Suspension from Official Quotation

25-Jun-2021	Trading Halt

24-Jun-2021	Results of Meeting

18-Jun-2021	Investor Presentation

17-Jun-2021	Proposed issue of securities - CPH

17-Jun-2021	Creso Pharma & Red Light Holland to Merge

16-Jun-2021	Trading Halt

11-Jun-2021	Creso Pharma completes US OTC dual listing

8-Jun-2021	Halucenex Expands its Clinical Trials Plans

4-Jun-2021	Distribution Agreement Expanded to Cover 14 Countries

3-Jun-2021	Creso & Halucenex welcome Californian Senate Bill

26-May-2021	Halucenex prepares North American market entry

24-May-2021	Proposed issue of Securities - CPH

24-May-2021	Update - Proposed issue of Securities - CPH

24-May-2021	Update - Proposed issue of Securities - CPH

24-May-2021	Update - Proposed issue of Securities - CPH

21-May-2021	Notice of Annual General Meeting/Proxy Form

21-May-2021	Creso Pharma signs Letter of Intent with Polvet

18-May-2021	Creso Launches New Product

17-May-2021	Mernova Awarded Craft Designation with OCS

14-May-2021	Halucenex Secures Additional Pharmaceutical Grade Psilocybin

12-May-2021	Trading Halt

12-May-2021	Pause in Trading

6-May-2021	Halucenex secures agreement with R&D partner Nucro-Technics

5-May-2021	Appendix 2A

30-Apr-2021	Quarterly Update & Appendix 4C

19-Apr-2021	Halucenex Update

14-Apr-2021	Commercial Agreement with Cannabis Queen, South Africa

12-Apr-2021	ASX Listing Rule 3.13.1 Notice Regarding AGM

12-Apr-2021	Halucenex Update

8-Apr-2021	Mernova secures new purchase orders & launches new products

6-Apr-2021	Creso appoints US executive to lead US entry strategy

1-Apr-2021	Secondary Trading Notice

1-Apr-2021	Appendix 2A

1-Apr-2021	Creso launches three new CBD tea products

31-Mar-2021	Creso continues positive progress with Halucenex

29-Mar-2021	Proposed issue of Securities - CPH

26-Mar-2021	Appendix 2A

26-Mar-2021	Proposed issue of Securities - CPH

26-Mar-2021	Creso Receives Firm Commitments to Raise $18M

24-Mar-2021	Trading Halt

23-Mar-2021	Creso to dual list on US OTC & Halucenex Update

19-Mar-2021	Appendix 2A

19-Mar-2021	New Mernova Purchase Orders & Launch of Pre-Roll Product

17-Mar-2021	Final Director's Interest Notice

17-Mar-2021	Halucenex Clinical Trial & Acquisition Update

15-Mar-2021	Change of Director's Interest Notice

15-Mar-2021	Halucenex Company Presentation

15-Mar-2021	Proposed issue of Securities - CPH

15-Mar-2021	Creso to Acquire Psychedelics Company, Halucenex

9-Mar-2021	Appendix 4G & Corporate Governance Statement

9-Mar-2021	Annual Report to shareholders

9-Mar-2021	Creso Signs North American Sports Distribution Deal

1-Mar-2021	Creso Signs With US Partner

1-Mar-2021	Preliminary Final Report

26-Feb-2021	Appendix 2A

19-Feb-2021	Appendix 2A

17-Feb-2021	New P.O.'s Demonstrate Strong Uptake

15-Feb-2021	CPH enters Pakistan with $2.5m Distribution Deal

12-Feb-2021	Appendix 2A

8-Feb-2021	Creso brings cannaqix sales inhouse to improve margins

5-Feb-2021	Secondary Trading Notice & Appendix 2A

3-Feb-2021	New POs demonstrate patient uptake

1-Feb-2021	CBD Oil legal in Australia - CPH to benefit

29-Jan-2021	Quarterly Update and Appendix 4C

27-Jan-2021	Change of Director's Interest Notice

22-Jan-2021	Appendix 2A

22-Jan-2021	Appendix 2A

21-Jan-2021	Update - Proposed issue of Securities - CPH

21-Jan-2021	Update - Proposed issue of Securities - CPH

21-Jan-2021	Update - Proposed issue of Securities - CPH

21-Jan-2021	Prospectus

19-Jan-2021	Creso secures POs for record start to FY2021

15-Jan-2021	Appendix 2A

12-Jan-2021	CPH secures $320,000 revenue from second PO in South Africa

11-Jan-2021	Appendix 2A

11-Jan-2021	Becoming a substantial holder

11-Jan-2021	Proposed issue of Securities - CPH

8-Jan-2021	Creso readies for US cannabis legislation reform

31-Dec-2020	Change of Director's Interest Notice

24-Dec-2020	Creso to enter the Hash market in Canada

23-Dec-2020	Appendix 2A

23-Dec-2020	Results of Meeting

21-Dec-2020	CPH Receives Regulatory Approval in Uruguay & Initial PO

18-Dec-2020	Appendix 2A

16-Dec-2020	CPH expands foot print in Canada & is now available online

15-Dec-2020	Creso Welcomes TGA Decision to Reschedule CBD

11-Dec-2020	Heads of Agreement to Unlock Australian Market

9-Dec-2020	CPH Enters Canada's Largest Recreational Market

7-Dec-2020	US House of Representatives Bill to Favour Creso in USA

3-Dec-2020	Creso set to benefit from UN decision to reclassify cannabis

2-Dec-2020	Creso Receives New Purchase Orders - EU

30-Nov-2020	EU Ruling to Benefit Creso

26-Nov-2020	Proposed issue of Securities - CPH

26-Nov-2020	TGA Update

23-Nov-2020	Notice of General Meeting/Proxy Form

30-Oct-2020	Quarterly Update and Appendix 4C

27-Oct-2020	Third Purchase Order from Nova Scotia Liquor Corporation

14-Oct-2020	Ceasing to be a substantial holder

14-Oct-2020	Israeli Market Update

13-Oct-2020	Ceasing to be a substantial holder

13-Oct-2020	Cleansing Prospectus

12-Oct-2020	Secured Debt Update

12-Oct-2020	Change of Director's Interest Notice x 2

12-Oct-2020	Appendix 2A

12-Oct-2020	Change in substantial holding

12-Oct-2020	Second Purchase Order from Pharma Dynamics, South Africa

9-Oct-2020	Second Retail PO from Nova Scotia Liquor Corporation

7-Oct-2020	Canopy Growth founder to join Creso

7-Oct-2020	Proposed issue of Securities - CPH

7-Oct-2020	Proposed issue of Securities - CPH

7-Oct-2020	Creso Pharma receives commitments totaling A$8.992m

6-Oct-2020	Becoming a substantial holder

6-Oct-2020	Ceasing to be a substantial holder

5-Oct-2020	Appendix 2A

2-Oct-2020	Results of Meeting

1-Oct-2020	Trading Halt

30-Sep-2020	Appendix 2A

22-Sep-2020	Addendum to Notice of General Meeting

21-Sep-2020	Mernova Receives First Retail Purchase Order From NSLC

10-Sep-2020	Creso welcomes TGA reclassification of CBD

1-Sep-2020	Appendix 2A

1-Sep-2020	Half Yearly Report and Accounts

28-Aug-2020	Proposed issue of Securities - CPH

27-Aug-2020	Notice of General Meeting/Proxy Form

14-Aug-2020	Company Update

12-Aug-2020	Agreement with DHS Business for Entry into Iberic Markets

3-Aug-2020	Appendix 2A

3-Aug-2020	Quarterly Activities Report and Appendix 4C

15-Jul-2020	Ceasing to be a substantial holder

10-Jul-2020	Mernova Receives US$625k Order for Shipment to Israel

3-Jul-2020	Redemption of Performance Shares

1-Jul-2020	Ceasing to be a substantial holder

30-Jun-2020	Ceasing to be a substantial holder

26-Jun-2020	Appendix 2A

26-Jun-2020	Becoming a substantial holder

26-Jun-2020	Proposed issue of Securities - CPH

26-Jun-2020	Mernova Milestone 2 Update

25-Jun-2020	Issue of Unlisted Securities

25-Jun-2020	Prospectus Offer Period Extension

25-Jun-2020	Appendix 2A

24-Jun-2020	Prospectus Offer Period Extension

24-Jun-2020	Appendix 2A

24-Jun-2020	Mernova Operational Update

24-Jun-2020	Cleansing Prospectus

23-Jun-2020	Appendix 2A

23-Jun-2020	Proposed issue of Securities - CPH

16-Jun-2020	Results of Meeting

15-Jun-2020	Ceasing to be a substantial holder

11-Jun-2020	Change in substantial holding

11-Jun-2020	Israeli Cannabis Legislation Update

10-Jun-2020	Update on Mernova Sales License

9-Jun-2020	Change of Director's Interest Notice

9-Jun-2020	Becoming a substantial holder

9-Jun-2020	Successful launch of Creso's Cannamics in South Africa

4-Jun-2020	Appendix 2A

3-Jun-2020	Appendix 2A

3-Jun-2020	Agreement for Entry into Brazilian Retail Market

2-Jun-2020	Proposed issue of Securities - CPH

2-Jun-2020	Cleansing Prospectus

2-Jun-2020	Placement and Corporate Update

2-Jun-2020	Appendix 2A

1-Jun-2020	Creso Pharma Receives Firm Commitments to Raise A$2.137M

1-Jun-2020	Appendix 2A

1-Jun-2020	Proposed issue of Securities - CPH

28-May-2020	Appendix 2A

28-May-2020	Proposed issue of Securities - CPH

28-May-2020	Appendix 2A

27-May-2020	Trading Halt

18-May-2020	Results of Meeting

13-May-2020	Update on Mernova Sales Licence

12-May-2020	Letter to Shareholders Regarding AGM

12-May-2020	Notice of Annual General Meeting/Proxy Form

11-May-2020	Trading Halt

11-May-2020	Pause In Trade

11-May-2020	Mernova Receives Retail Sales License from Health Canada

30-Apr-2020	Quarterly Update and Appendix 4C (Replacement)

30-Apr-2020	Quarterly Update and Appendix 4C

20-Apr-2020	Appendix 2A

20-Apr-2020	Cleansing Prospectus

20-Apr-2020	Proposed issue of Securities - CPH

20-Apr-2020	Proposed issue of Securities - CPH

20-Apr-2020	Proposed issue of Securities - CPH

20-Apr-2020	Proposed issue of Securities - CPH

20-Apr-2020	Funding Update

20-Apr-2020	Israeli JV Update

15-Apr-2020	Notice of General Meeting/Proxy Form

14-Apr-2020	L1 Capital Collateral Purchase Notice & Top-Up Notice

14-Apr-2020	Pause in Trading

14-Apr-2020	Binding LOI to Expand Distribution into Pakistan

8-Apr-2020	ASX Listing Rule 3.13.1 Notice Regarding AGM

7-Apr-2020	Appendix 3G

7-Apr-2020	Creso Completes AUD 200,000 Order of anibidiol to Virbac

2-Apr-2020	Creso Pharma Outlines Response to COVID-19

2-Apr-2020	Pause in Trading

1-Apr-2020	Mernova Receives C$775k Order for First Shipment to Israel

26-Mar-2020	First Shipment of cannaQIX to South Africa For Launch in Q2

24-Mar-2020	Creso Pharma to Launch CBD Hemp Tea

12-Mar-2020	Ceasing to be a substantial holder - Correction

11-Mar-2020	Ceasing to be a substantial holder

11-Mar-2020	Creso Strengthens Mernova Senior Management Team

10-Mar-2020	Trading Halt

10-Mar-2020	Pause in Trading

6-Mar-2020	Becoming a substantial holder

3-Mar-2020	Creso Signs Agreement to Market its Products in Scandinavia

2-Mar-2020	Termination of Israeli Joint Venture

28-Feb-2020	Appendix 4G & Corporate Governance Statement

28-Feb-2020	Preliminary Report & Annual Report to shareholders

19-Feb-2020	Change of Director's Interest Notice

18-Feb-2020	Appendix 2A

18-Feb-2020	Change in substantial holding

14-Feb-2020	Mernova Milestone 2 Achieved

12-Feb-2020	Issue of Unquoted Securities

11-Feb-2020	Proposed issue of Securities - CPH

11-Feb-2020	Appendix 2A

11-Feb-2020	Appendix 2A

11-Feb-2020	Creso to launch hemp product for equines and large animals

11-Feb-2020	Supplementary Prospectus

7-Feb-2020	Prospectus

6-Feb-2020	Technological Breakthrough for Human Health Products

5-Feb-2020	Appendix 2A

5-Feb-2020	Proposed issue of Securities - CPH

5-Feb-2020	Creso Pharma Secures Further Funding

30-Jan-2020	New Constitution

28-Jan-2020	Results of Meeting

28-Jan-2020	Creso exceeds milestone of 2.5m cannaQIX lozenges sold

23-Jan-2020	Change in substantial holding

21-Jan-2020	Re-engagement of Corporate Advisor

21-Jan-2020	Creso exceeds milestone of 3m anibidiol doses sold in Europe

17-Jan-2020	Quarterly Update and Appendix 4C

13-Jan-2020	Addendum to Notice of General Meeting

8-Jan-2020	Release of Securities From Voluntary Escrow

8-Jan-2020	Response to ASX Price Query

31-Dec-2019	Convertible Note Facility Drawdown

23-Dec-2019	Notice of General Meeting/Proxy Form

19-Dec-2019	Change in substantial holding

12-Dec-2019	Release of Securities From Voluntary Escrow

9-Dec-2019	Creso enters the African continent with cannaQIX products

5-Dec-2019	Commencement of sales of cannaQIX 50 in Australia with BHC

3-Dec-2019	Corporate Presentation - December 2019

2-Dec-2019	Appendix 3B

2-Dec-2019	Placement under ASX Listing Rule 7.1A

2-Dec-2019	Appendix 3B

2-Dec-2019	Reinstatement to Official Quotation

2-Dec-2019	Update on Strategy and Plans to Accelerate Global Operations

28-Nov-2019	Appendix 3B

28-Nov-2019	Waiver from ASX Listing Rule 10.1

28-Nov-2019	Disclosure Document - Debt Note Offer & Cleansing Offer

12-Nov-2019	Termination of Scheme Implementation Agreement

11-Nov-2019	Adjournment of Scheme Meetings

8-Nov-2019	Update on Voluntary Suspension

5-Nov-2019	Suspension from Official Quotation

1-Nov-2019	Trading Halt

1-Nov-2019	Pause in Trade

17-Oct-2019	First Shipment of 10% Medicinal CBD Oil in New Zealand

14-Oct-2019	Quarterly Update & Appendix 4C

4-Oct-2019	Scheme Booklet (Replacement)

4-Oct-2019	Scheme Booklet

4-Oct-2019	Reinstatement to Official Quotation

3-Oct-2019	Update on Proposed Acquisition by PharmaCielo

27-Sep-2019	Update on Proposed Acquisition by PharmaCielo

18-Sep-2019	Voluntary Suspension

16-Sep-2019	Trading Halt

16-Sep-2019	Pause in Trading

16-Sep-2019	Creso Granted Processing Licence for its Mernova Facility

4-Sep-2019	Release of Securities From Voluntary Escrow

26-Aug-2019	Half Yearly Report and Accounts

22-Aug-2019	Creso Signs with Pharma Dynamics for cQIX in South Africa

20-Aug-2019	Creso Receives PCLO's First Commercial CBD Export into EU

8-Aug-2019	Additional Information on Medleaf Distribution Agreement

6-Aug-2019	Distribution Agreement with Medleaf NZ for CBD Products

2-Aug-2019	Change of Director's Interest Notice

1-Aug-2019	First Order of cannaQIX50 from Burleigh Heads Cannabis

31-Jul-2019	Cleansing Statement and Appendix 3B

24-Jul-2019	Quarterly Update & Appendix 4C

15-Jul-2019	Change in substantial holding

15-Jul-2019	Change in substantial holding

12-Jul-2019	Cleansing Statement and Appendix 3B

10-Jul-2019	Becoming a substantial holder

8-Jul-2019	Appendix 3Y x 4

3-Jul-2019	Creso Repays Debt in Preparation for Acquisition & App 3B

2-Jul-2019	Creso Begins Revenue Generation from Canadian Cannabis Sales

7-Jun-2019	Creso Pharma To Be Acquired

4-Jun-2019	Release of Securities From Voluntary Escrow

31-May-2019	Results of Meeting

23-May-2019	Creso Harvests First Cannabis Crop in Canada

30-Apr-2019	BHC Distribution Agreement & Australian Import Permit

29-Apr-2019	Quarterly Update & Appendix 4C

29-Apr-2019	Notice of Annual General Meeting/Proxy Form

23-Apr-2019	Brazil Import Licence - Additional Information

18-Apr-2019	Brazil Import Licence Granted For cannaQIX

15-Apr-2019	Creso Pharma Canadian Cultivation Update

11-Apr-2019	Additional Information on Secured Loans

11-Apr-2019	Creso to Raise AUD5.35m via Secured Loans

9-Apr-2019	Trading Halt

5-Apr-2019	Response to ASX Aware Query

2-Apr-2019	Commercial Progress Across Premium Product Categories

27-Mar-2019	Appendix 4G & Corporate Governance Statement

25-Mar-2019	Annual Report to shareholders

6-Mar-2019	Release of Securities From Voluntary Escrow

28-Feb-2019	CEO's Report on Operations & Appendix 4E

18-Feb-2019	Creso Granted License to Cultivate Cannabis

14-Feb-2019	Strategic Collaboration for CBD products with Hempmate Switz

13-Feb-2019	Strategic Collaboration with Burleigh Heads Cannabis

12-Feb-2019	Reinstatement to Official Quotation

12-Feb-2019	Clarification and Reinstatement to Trading

6-Feb-2019	Suspension Update

4-Feb-2019	Suspension from Official Quotation

1-Feb-2019	Cleansing Statement & Appendix 3B

1-Feb-2019	Trading Halt

1-Feb-2019	Pause In Trading

1-Feb-2019	Colombian Partnership and Appointment of Medical Advisor

31-Jan-2019	Quarterly Update & Appendix 4C

31-Jan-2019	Placement Update, Cleansing Statement & Appendix 3B

30-Jan-2019	Creso and CLV Expand the OBMJ Beers to Switzerland

24-Jan-2019	Creso Raises $3 Million in Institutional Placement

22-Jan-2019	Trading Halt

21-Jan-2019	Creso Signs Supply Agreement with TerrAscend Canada

9-Jan-2019	Creso further builds medical cannabis in NZ with Medleaf

7-Jan-2019	Strategic Collaboration in Sri Lanka for Medical Cannabis

2-Jan-2019	Creso builds on Israel's new Med Cannabis export law

20-Dec-2018	Settlement of Kunna Canada Acquisition - incl Appendix 3B

20-Dec-2018	US CBD hemp market opens to Creso

19-Dec-2018	Update on Creso Pharma Canadian growing facility

17-Dec-2018	Secondary Trading Notice & Appendix 3B

17-Dec-2018	Commercialisation of Animal Health Products Commences

4-Dec-2018	Canada TSX-V Roadshow Presentation

3-Dec-2018	Creso Pharma to Dual List on TSX-V Canada

28-Nov-2018	Interview with Creso COO

14-Nov-2018	Exclusive Distribution Agreement for CPH Veterinary Products

1-Nov-2018	Creso to launch its first medical cannabis product in Brazil

31-Oct-2018	Quarterly Activities Report and Appendix 4C

30-Oct-2018	CPH Establishes Edible Cannabis Product R&D Centre

22-Oct-2018	Appendix 3B - Release from Escrow

19-Oct-2018	Change of Company Secretary

18-Oct-2018	Cleansing Statement & Appendix 3B - Exercise of Options

17-Oct-2018	Creso welcomes legalisation of recreational cannabis, Canada

16-Oct-2018	Results of Meeting

11-Oct-2018	Appendix 3B

9-Oct-2018	Old Boy Mary Jane Beer Launch in London, Berlin

8-Oct-2018	Securities to be released from escrow

8-Oct-2018	Licence application accepted & Construction Finance Loan

18-Sep-2018	FNN Interview with Chief Operating Officer

12-Sep-2018	Appendix 3B - Quotation of Options

11-Sep-2018	Appendix 3B - Options Entitlement Issue Shortfall

11-Sep-2018	Update on Colombian Acquisition & Notice of General Meeting

5-Sep-2018	Creso Pharma Lifestyle Portfolio Update

31-Aug-2018	Quotation of Entitlement Issue Options

28-Aug-2018	Half Yearly Report and Accounts

28-Aug-2018	Appendix 3B - Quotation of Options

27-Aug-2018	Appendix 3Y x 4 - Options Entitlement Issue

21-Aug-2018	Appendix 3B

21-Aug-2018	UK commercialisation of cannaQIX with Pharmacare

17-Aug-2018	Entitlement Issue Shortfall Notice

14-Aug-2018	Commercial agreement for cannaQIX in Austria & East Europe

3-Aug-2018	Dispatch of Entitlement Issue Prospectus

2-Aug-2018	Creso to launch cannaQIX in Israel and the Middle East

31-Jul-2018	Quarterly Activities Report & Appendix 4C

30-Jul-2018	Appendix 3Y - Vesting of Performance Rights

27-Jul-2018	Cleansing Statement & Appendix 3B

26-Jul-2018	Entitlement Issue - Letter to Option holders

26-Jul-2018	Entitlement Issue - Letter to Ineligible Shareholders

26-Jul-2018	Entitlement Issue - Letter to Eligible Shareholders

25-Jul-2018	Appendix 3B

25-Jul-2018	Prospectus - Entitlement Issue

25-Jul-2018	Investor Presentation

23-Jul-2018	Appendix 3Y - Vesting of Performance Rights

23-Jul-2018	Conversion of Performance Rights & Appendix 3B

23-Jul-2018	Options Entitlement Issue

23-Jul-2018	Creso to finalise Colombian Acquisition

17-Jul-2018	Creso now trading on the Frankfurt Stock Exchange

16-Jul-2018	Appendix 3B

2-Jul-2018	Creso launches cannaQIX in New Zealand

25-Jun-2018	Creso JV launches infused terpene craft beers and beverages

21-Jun-2018	Creso welcomes decision to legalise Cannabis use in Canada

14-Jun-2018	Creso appoints Chief Operating Officer, Americas

12-Jun-2018	Licence to cultivate Medicinal Cannabis in Colombia granted

31-May-2018	Results of Meeting

31-May-2018	Update on Colombian Acquisition

21-May-2018	Commercial start of cannaQIX in BENELUX with first orders

16-May-2018	Creso expands into Israeli Medical Cannabis

14-May-2018	Trading Halt

2-May-2018	Notice of Annual General Meeting

30-Apr-2018	Quarterly Activities Report & Appendix 4C

30-Apr-2018	Global Expansion of anibidiol

18-Apr-2018	Creso's JV to launch Global Beers and Tonics

16-Apr-2018	Corporate Update

6-Apr-2018	Update on Colombian Acquisition

15-Mar-2018	Creso launches cannaDOL product range

27-Feb-2018	Appendix 4G

27-Feb-2018	Corporate Governance Statement

27-Feb-2018	Annual Report and Appendix 4E

27-Feb-2018	Creso reports first revenues from cannaQIX and anibidiol

19-Feb-2018	Completion of Mernova acquisition

14-Feb-2018	Market Update on Colombian Operations

13-Feb-2018	Mernova Update

12-Feb-2018	Company Update

9-Feb-2018	Trading Halt

1-Feb-2018	Morningstar Quantitative Equity Report

31-Jan-2018	Quarterly Activities Report & Appendix 4C

29-Jan-2018	Investor Presentation

17-Jan-2018	Commercialisation Agreement signed for UK launch of cannaQIX

11-Jan-2018	Launch of JV for cannabis-derived beverage market

5-Jan-2018	CPH Welcomes AU Govt Law

21-Dec-2017	Cleansing Statement and Appendix 3B

21-Dec-2017	Closure of Share Purchase Plan

19-Dec-2017	CommSec Interview

18-Dec-2017	Colombian Medicinal Cannabis Acquisition

14-Dec-2017	Trading Halt

13-Dec-2017	Mernova Construction Update - Canada

11-Dec-2017	Results of Meeting

4-Dec-2017	Creso signs distribution agreement in Switzerland - CannaQIX

1-Dec-2017	Cleansing Statement, Appendix 3B and LR 3.10.5A Disclosure

29-Nov-2017	Share Purchase Plan

29-Nov-2017	Creso signs binding LOI with Baltic Beer & LGC Capital

28-Nov-2017	Cleansing Statement & Appendix 3B - Exercise of Options

28-Nov-2017	Cleansing Statement - SPP

28-Nov-2017	Reinstatement to Official Quotation

28-Nov-2017	Oversubscribed Placement, SPP and Company Update

27-Nov-2017	Suspension from Official Quotation

22-Nov-2017	Trading Halt

22-Nov-2017	Creso enters Australia Pharma Market

20-Nov-2017	China Strategic Commercial Distribution Agreement Signed

15-Nov-2017	Independent Investment Research Report on Creso

14-Nov-2017	Creso launches first animal health product in Switzerland

13-Nov-2017	Creso welcomes Canadian Tax Reform on Cannabis

9-Nov-2017	Notice of General Meeting

9-Nov-2017	Creso Pharma and LGC Capital announce Strategic Alliance

7-Nov-2017	Research Collaboration with University of Wollongong

1-Nov-2017	Cleansing Statement & Appendix 3B

27-Oct-2017	Creso Market Update

25-Oct-2017	Quarterly Activities Report & Appendix 4C

18-Oct-2017	Appendix 3B - Release of securities from escrow

17-Oct-2017	Morningstar releases Independent Research Report on Creso

13-Oct-2017	Cleansing Statement

13-Oct-2017	Appendix 3B

3-Oct-2017	Securities to be released from escrow

28-Sep-2017	Creso completes DD of Mernova - On track for Completion

21-Sep-2017	Change of registered office address

7-Sep-2017	Investor Presentation

28-Aug-2017	Half Yearly Report and Accounts

9-Aug-2017	Market Update

7-Aug-2017	Creso to Launch Animal Health Products in Switzerland

1-Aug-2017	Q and A on Mernova Medicinal Inc Acquisition

1-Aug-2017	FNN Interview with Chairman and COO - Mernova Medicinal

27-Jul-2017	Cleansing Notice

27-Jul-2017	Appendix 3B

27-Jul-2017	Results of General Meeting

27-Jul-2017	Investor Presentation - Mernova Acquisition

27-Jul-2017	Creso expands into Canada with acquisition of Mernova

26-Jul-2017	Trading Halt

24-Jul-2017	Quarterly Activities Report & Appendix 4C

18-Jul-2017	Appendix 3B

28-Jun-2017	Securities due for release from escrow

28-Jun-2017	Investor Presentation - Product Launches

26-Jun-2017	General Meeting Proxy Form

26-Jun-2017	Notice of General Meeting

26-Jun-2017	Appendix 3B - Release of Securities from Escrow

14-Jun-2017	Market Update - Human & Animal Health Product Development

8-Jun-2017	Securities due for Release from Escrow

2-Jun-2017	Investor Presentation - June 2017

1-Jun-2017	Creso first to export medicinal Cannabis from Switzerland

11-May-2017	LOI signed to expand Creso's offering to Australian Market

5-May-2017	Company Update

2-May-2017	CPH successfully imports Australia's first Cannabis shipment

28-Apr-2017	Quarterly Activities Report & Appendix 4C

24-Apr-2017	Asia Investor Roadshow

19-Apr-2017	Appendix 3B - Share Purchase Plan

13-Apr-2017	Becoming a substantial holder

12-Apr-2017	Cleansing Notice

12-Apr-2017	Appendix 3B & Listing Rule 3.10.5A Disclosure

12-Apr-2017	Results of Annual General Meeting

10-Apr-2017	Share Purchase Plan Closes Oversubscribed

5-Apr-2017	Extension of Closing Date for Share Purchase Plan

4-Apr-2017	Creso appoints Chief Operating Officer

3-Apr-2017	Becoming a substantial holder

3-Apr-2017	FNN Interview with Chairman - Medicinal Cannabis Market

31-Mar-2017	Securities due for release from escrow

31-Mar-2017	Ceasing to be a substantial holder

31-Mar-2017	Change of Director's Interest Notice x 5

31-Mar-2017	Cleansing Statement - Placement

31-Mar-2017	Appendix 3B

30-Mar-2017	Response to ASX Aware Letter

28-Mar-2017	Share Purchase Plan

27-Mar-2017	Cleansing Notice - Share Purchase Plan

27-Mar-2017	Oversubscribed Placement to raise $8m and SPP

23-Mar-2017	Trading Halt

22-Mar-2017	Creso Signs Sales & Distribution Agreement in Brazil

20-Mar-2017	Trading Halt

20-Mar-2017	Trading Halt

17-Mar-2017	Independent Investment Research Report

16-Mar-2017	Sales Update

13-Mar-2017	Notice of Annual General Meeting

13-Mar-2017	Australian Roadshow Presentation

8-Mar-2017	FNN Interview with CEO regarding Domaco

7-Mar-2017	Creso Signs Binding LOI with Domaco

3-Mar-2017	Trading Halt

1-Mar-2017	Appointment to Creso's Scientific Advisory Board

28-Feb-2017	Annual Report and Appendix 4E

28-Feb-2017	Appendix 4G

28-Feb-2017	Corporate Governance Statement

27-Feb-2017	Appendix 3B - Release of Securities from Escrow

24-Feb-2017	Granting of Federal Import Licence to Exclusive Facilitator

14-Feb-2017	Progress with Creso's Human Health Product

8-Feb-2017	Release of Escrowed Securities

3-Feb-2017	Australian LOI signed for Import & Sale of Cannabis Products

2-Feb-2017	Reinstatement to Official Quotation

2-Feb-2017	Australian LOI signed for Import & Sale of Cannabis Products

2-Feb-2017	Request for Voluntary Suspension

2-Feb-2017	Suspension from Official Quotation

31-Jan-2017	Trading Halt

30-Jan-2017	Quarterly Activities Report & Appendix 4C

24-Jan-2017	Appendix 3B

19-Jan-2017	Appendix 3B - Release of Securities from Escrow

18-Jan-2017	Creso Secures EU Registration for Animal Health Products

16-Jan-2017	Trading Halt

9-Jan-2017	Release of Escrowed Securities

8-Dec-2016	Revenue Generation continues for Creso's Hemp Products

6-Dec-2016	Appendix 3B

23-Nov-2016	Executive Directors Interview with Finance News Network

17-Nov-2016	LOI with Canadian Medical Cannabis Group for EU Market

14-Nov-2016	Change of Registered Address

14-Nov-2016	Investor Presentation

10-Nov-2016	IPO Prospectus

7-Nov-2016	Creso Secures Binding LOI for Animal Health Products

31-Oct-2016	Quarterly Activities Report & Appendix 4C

31-Oct-2016	Commercial Distribution Agreement to bring First Revenues

27-Oct-2016	Binding LOI for Commercialisation of Nutraceutical Product

26-Oct-2016	Trading Halt

24-Oct-2016	Initial Director's Interest Notice x 5

24-Oct-2016	Becoming a substantial holder

24-Oct-2016	Investor Presentation

21-Oct-2016	FNN Interview with Executive Directors

20-Oct-2016	Creso Commences Trading on the ASX

18-Oct-2016	Performance Rights Plan Terms & Conditions

18-Oct-2016	Terms & Conditions of Securities

18-Oct-2016	Restricted Securities

18-Oct-2016	Confirmations

18-Oct-2016	Hemp Industries accounts

18-Oct-2016	Updated pro-forma balance sheet

18-Oct-2016	Top 20 Holders

18-Oct-2016	Distribution Schedule

18-Oct-2016	Appendix 1A and Information Form & Checklist

18-Oct-2016	Pre-quotation Disclosure

18-Oct-2016	ASX Notice - Admission & Commencement of Official Quotation

18-Oct-2016	Admission to Official Quotation